June 11, 2008 15:32 ET

xyzmo Joins SAFE-BioPharma Vendor Partner Program

JERSEY CITY, NJ--(Marketwire - June 11, 2008) - xyzmo, the leading international digital and e-signature technology provider, announced today that they have become a vendor partner of SAFE-BioPharma Association, the non-profit association that created and manages the SAFE-BioPharma™ digital identity and signature standard for the pharmaceutical and healthcare industries.

xyzmo's unique technology provides three levels of authentication. In addition to the security provided by the digital certificate and the pin and password of each user, xyzmo includes within its digital seal a handwritten signature with its biometric attributes such as speed, pressure, angle, and acceleration. All data acquired during the sealing process is stored within the signed and sealed standard document.

Document integrity can be verified and assured at any point in time during the document's lifetime via the internet without the need of any additional software. xyzmo SIGNificant Server is fully web enabled, therefore no local installation or maintenance is necessary. The functionality of the software server allows for easy integration.

Additionally, a signatory can be identified in real-time based on his or her handwritten signature biometric attributes when signing on a simple signature pad compared to an established signature profile. For example, with this technology it can be ensured that a doctor or a lab-technician who is obligated to sign a specific document, signs himself and not someone else on his or her behalf.

xyzmo's technology enables SAFE-BioPharma member companies to meet their paperless initiatives as well as help to enforce proper signature procedures while enabling compliancy with the laws existing in the highly regulated pharmaceutical and healthcare industries.

"Our partnership with SAFE-BioPharma establishes tremendous credibility for xyzmo within the pharmaceutical and healthcare community and strengthens our presence on the US market. Our unique technology results in immediate cost savings by eliminating paper-based processes and in parallel reduces the risk of fraud and accelerates new drug development timelines," commented Juergen Hirtenfelder, the Managing Director of xyzmo US LLC based in Jersey City, NJ.

Ken Bald, Sales Director for Pharmaceutical and Healthcare at xyzmo had this to say, "We are extremely pleased to introduce our digital signature technology to the impressive list of SAFE members."

"We are pleased to welcome xyzmo as a vendor partner. The company's technology is compatible with the SAFE-BioPharma digital standard and offers our member companies additional options for secure signing," said Mollie Shields-Uehling, President and CEO, SAFE-BioPharma Association.

About xyzmo

Stemming from a hundred year old tradition of signing and stamping, xyzmo's technology fits companies of all sizes and offers advanced digital signature technology that saves money, time and trees. Learn what's new with xyzmo by visiting

About SAFE-BioPharma Association

SAFE-BioPharma Association is the non-profit association that created and manages the SAFE-BioPharma™ digital identity and signature standard for the pharmaceutical and healthcare industries. The SAFE-BioPharma industry standard is used to mitigate legal, regulatory and other business risk associated with business-to-business and business-to-regulator electronic transactions. It facilitates interoperability by providing a secure, enforceable, and regulatory-compliant way to verify identities of parties involved in electronic transactions. SAFE-BioPharma's vision is to be a catalyst in transforming the biopharmaceutical and healthcare communities to a fully electronic business environment by 2012. The Association's members include Amgen, AstraZeneca, Bristol-Myers Squibb, Genzyme, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, Procter & Gamble, Roche and Sanofi-Aventis. For more information, visit

SAFE-BioPharma™ is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association.

Contact Information